Early value dossiers for medical technologies
The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders
Recent news and posts
Rapid HTAs of five medical devices released in Tuscany in November 2024
The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With the regional decree 25504 of November 18, 2024, Tuscany Regional Healthcare published five rapid HTA reports (four new assessments and one reassessment) of medical devices in the cardiovascular, ophthalmology, ENT, and dermatology areas.
Examples of evaluated technologies are provided below:
- Propel Contour 370mcg mometasone furoate bioabsorbable implant by Intersect ENT for patients with chronic rhinosinusitis following sinus surgery to maintain patency of the ostium of the frontal sinuses;
- Axiostat Vascular, chitosan dressing to control bleeding from vascular access sites by Axio Biosolutions for pediatric patients following femoral puncture procedures.
See the regional decree and all assessments in Italian and English here.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.